文献速递肾小球疾病

扁桃体切除联合免疫抑制改善高危IgA肾病白人患者结局

Tonsillectomy and immunosuppression improve outcomes in Caucasians with high-risk IgA nephropathy.
PubMed 文献 · Nephrol Dial Transplant · 2026-01-01

这项前瞻性非随机对照研究纳入221例高危原发性IgA肾病白人患者,比较免疫抑制治疗(IST)单用与联合扁桃体切除(TE+IST)的疗效。中位随访33个月,TE+IST组早期总体缓解率95.2%显著高于IST组72.6%,疾病进展风险显著降低(调整HR 0.126)。结论提示TE联合IST可能有效诱导缓解并延缓高危IgA肾病患者进展。

要点

  • 高危IgA肾病白人患者中,TE+IST组早期总体缓解率95.2%,显著高于IST单用组72.6%。
  • TE+IST组疾病进展发生率3.5%,显著低于IST单用组28.9%(调整HR 0.126)。
  • TE+IST组缓解时间较IST单用组缩短一半,早期完全缓解风险显著更高。

核心结论

  • 扁桃体切除联合免疫抑制治疗可能对高危IgA肾病患者有效诱导缓解并延缓疾病进展。

研究设计与样本

  • 前瞻性非随机对照研究纳入221例高危原发性IgA肾病白人患者,中位年龄35±11岁,52%为男性。
  • 患者接受免疫抑制治疗(72.3%为糖皮质激素单药)不加扁桃体切除(对照组n=136)或加扁桃体切除(TE+IST组n=85)。
  • 中位随访33个月(四分位距15-69),采用Kaplan-Meier、Cox回归、倾向性评分1:1匹配和逆概率治疗加权(IPTW)分析。

主要发现

  • IST组和TE+IST组早期总体缓解率分别为72.6%和95.2%(P < .001)。
  • TE+IST组缓解时间较IST组缩短2倍(P < .001)。
  • 调整Cox模型中,TE+IST组早期总体缓解的HR为3.364(95%CI 2.302-4.917),早期完全缓解的HR为6.315(95%CI 2.620-15.224)。
  • TE+IST组疾病进展3例(3.5%),IST组39例(28.9%),调整HR为0.126(95%CI 0.037-0.427)。
  • 倾向性评分1:1匹配组和IPTW Cox模型分析结果相似。

临床怎么用

  • 对于高危原发性IgA肾病白人患者,可考虑在免疫抑制治疗基础上联合扁桃体切除以诱导缓解并延缓进展。

局限性

  • 研究为非随机对照设计,尽管采用倾向性评分匹配和IPTW校正,仍可能存在残余混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Considering the absence of such data, this study explored the effectiveness of immunosuppressive therapy (IST) and tonsillectomy (TE) in Caucasians with high-risk immunoglobulin A nephropathy (IgAN). METHODS: The prospective non-randomised comparative study enrolled incident Caucasian patients with a definite clinical and histological diagnosis of primary IgAN (n = 221, age 35 ± 11 years, 52% male) at high risk of progression. All patients received IST (72.3% glucocorticoid monotherapy) without TE (control group, n = 136) or with TE (TE + IST; experimental group, n = 85). The median follow-up period was 33 months (interquartile range 15-69). Kaplan-Meier and Cox regression analyses combined with pseudo-randomisation methods (1:1 matching of comparison groups) and inverse probability of treatment weighting (IPTW) were applied to assess the effects of TE + IST on primary outcomes: complete remission (CR), overall (complete or partial) remission (OR) and disease progression (>40% decrease in estimated glomerular filtration rate or end-stage kidney disease). RESULTS: The rates of early OR in the IST and TE + IST groups were 72.6% and 95.2%, respectively (P < .001). In the Kaplan-Meier analyses, the time to remission was 2-fold shorter in the TE + IST group (P < .001). In the adjusted Cox models, the probabilities of early OR and CR were significantly higher in the tonsillectomy group compared with IST alone {hazard ratio [HR] 3.364 [95% confidence interval (CI) 2.302-4.917] and HR 6.315 [95% CI 2.620-15.224], respectively}. The disease progression was registered in 3 patients (3.5%) in those on the combination therapy compared with 39 patients (28.9%) in the IST group [adjusted HR 0.126 (95% CI 0.037-0.427)]. Analyses performed in propensity score 1:1 matched groups and IPTW Cox models yielded similar results. CONCLUSIONS: Tonsillectomy and immunosuppressive therapy may be effective for remission induction and delaying progression in high-risk IgAN patients.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Kochoyan ZS, Dobronravov VA. Tonsillectomy and immunosuppression improve outcomes in Caucasians with high-risk IgA nephropathy. Nephrol Dial Transplant. 2026. PMID: 41400194. doi:10.1093/ndt/gfaf262

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。